Data layers Raw facts Calculated Model prediction AI interpretation

Cross-Market Price Comparison

Other Listed Market To be extracted
Other Market Stock Code To be extracted
H-Share Offer PriceTo be extracted
Other Market PriceLoading...
Reference Exchange RateLoading...
H-Share Offer Price Premium/Discount vs Other MarketLoading...

Company Overview

Stock NameCMS
Stock Code00867
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities一家立足於中國的領先醫藥服務公司,專門從事營銷、推廣及銷售國內外專業製藥公司的處方藥品,提供獨家營銷、推廣及銷售服務,包括一對一拜訪醫生、舉辦醫學研討會和贊助行業會議等。
Listing Date2010-09-28
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國深圳市南山區深圳高新科技園北區朗山路11號同方信息港A棟6樓、8樓 郵編518057
Business Address (Hong Kong)香港北角英皇道510號港運大廈21樓2106室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.cms.net.cn
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingYes (AIM)

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 5.06 / shares
Offer Price RangeTo be extracted
Lot Size800 shares
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2010-09-20 to 2010-09-20
Global Offering Shares200,000,000 shares
HK Public Offer Shares (Initial)20,000,000 shares (10.0%)
Public Offer Lots (Initial)25,000lots (Pool A12,500lots,Pool B12,500lots)
International Placing Shares (Initial)180,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,123,691,440 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,012,000,000

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap HK$ 28.71B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利约20.8百万美元
Period-End Cash BalanceTo be extracted
Listing Expenses~HK$ 54,100,000
Listing Expenses / Funds Raised~5.35%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 USD
Income Statement
Item 2007200820092010-06
Revenue 51,74772,60096,45461,195
Cost of sales -18,149-27,835-35,596-23,970
Gross profit 33,59844,76560,85837,225
Other income and gains, net 1,2802,690662546
Selling and distribution expenses -13,934-18,631-24,840-13,318
Administrative expenses -5,947-6,940-7,399-3,274
Net finance costs -301-226-390-336
Share of associates and JVs 561523042
Profit before tax 10,34619,53526,92619,689
Income tax expense -1,672-4,487-6,096-4,355
Profit for the year 8,67415,04820,83015,334
Profit attributable to owners 8,68514,94620,68415,230
Balance Sheet
Item 2007200820092010-06
Cash and cash equivalents 17,60120,10015,11310,340
Trade and bills receivables 19,30527,68432,79441,485
Inventories 10,6775,94511,06017,437
Total current assets 47,76755,00477,12088,308
Total assets 41,84459,73960,98972,229
Total current liabilities 13,10010,75529,78831,371
Total equity 41,84452,72153,93464,954
Equity attributable to owners 42,00052,79053,73364,954
Interest-bearing borrowings 0016,51716,346
Cash Flow Statement
Item 2007200820092010-06
Net cash from operating activities 6,57210,17515,5494,673
Net cash from investing activities -1,861-1,744-16,616-2,812
Net cash from financing activities 3,072-7,219-4,022-6,937
Net increase in cash 7,7831,212-5,089-5,076
Depreciation of PP&E 637772898380
Amortisation of intangible assets 597931,115419
Purchase of PP&E -795-959-280-101
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 5.64
First Day OpenHK$ 5.85
First Day Change11.46%
First Day Volume211863000.0
First Day Turnover1255170000.0
Use of Proceeds
1、約8.3%或67.5百萬港元,將用于通過聘請更多合資格及專業員工及擴大醫院覆蓋范圍和地域范圍; 2、約12.5%或101.7百萬港元,將用于興建新培訓及會議中心以供進行醫生培訓、醫學會議及其他推廣活動以及員工培訓; 3、約8.3%或67.5百萬港元,將用于更換、改善或升級信息管理系統的軟硬件; 4、約33.3%或270.9百萬港元,將用于收購在中國推廣銷售藥品的獨家授權及尋求并購合適制藥公司的機會。 5、在取得理想的CMS024臨床進展后,約16.8%或136.7百萬港元,將用于興建一個生產廠房以供制造公司自行生產的藥品。 6、約10%或87.8百萬港元,將用于撥款向供應商采購進口藥品以滿足中國市場對我們的授權引進產品日益增加的需求; 7、約10%或81.3百萬港元,將用作我們的營運資金及其他一般企業用途;

Underwriting Syndicate

Sole Sponsor (1)
UBS Securities Hong Kong Limited CE BIN466
Overall Coordinators (1)
UBS Securities Hong Kong Limited CE BIN466
Joint Bookrunners (1)
UBS Securities Hong Kong Limited CE BIN466
Joint Lead Managers (1)
UBS Securities Hong Kong Limited CE BIN466

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman林剛—
Company Secretary許永善—
No director data available.

Major Shareholders

Major Shareholders & Holdings林剛(46.39%)
About this page

This page shows CMS (00867) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect